Aramark (ARMK)
(Delayed Data from NYSE)
$33.29 USD
+1.13 (3.51%)
Updated May 10, 2024 04:00 PM ET
After-Market: $33.30 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
ARMK 33.29 +1.13(3.51%)
Will ARMK be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ARMK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARMK
Aramark (ARMK) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Aramark (ARMK) Surpasses Q2 Earnings Estimates
ARMK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Countdown to Aramark (ARMK) Q2 Earnings: Wall Street Forecasts for Key Metrics
Cintas (CTAS), Google Cloud Unite on gen AI Knowledge Center
Has Aramark (ARMK) Outpaced Other Consumer Staples Stocks This Year?
Other News for ARMK
Aramark's Dividend Analysis
Helping Students Launch Careers: Aramark Collegiate Hospitality and USF’s School of Hospitality and Tourism Partner for Post-Grad Success
J.P. Morgan Sticks to Its Buy Rating for ARAMARK Holdings (ARMK)
3 Spinoff Stocks That Failed to Impress – Is the Model Broken?
Ex-Dividend Reminder: Aramark, Exelon and Bio-Techne